On December 1, 2003, Ethan B. Russo, a Senior Medical Advisor at GW Pharmaceuticals submitted a study entitled "Clinical Endocannabinoid Deficiency (CECD): Can this Concept Explain Therapeutic Benefits of Cannabis in Migraine, Fibromyalgia, Irritable Bowel Syndrome and other Treatment-Resistant Conditions?" This study examines the concept of clinical endocannabinoid deficiency (CECD).
The study reported investigation into the prospect that endocannabinoid deficiency could underlie the pathophysiology of migraine, fibromyalgia, irritable bowel syndrome, and other functional conditions alleviated by clinical cannabis.
With consideration of the issues of migraine, fibromyalgia, irritable bowel syndrome, and other functional conditions many laypersons have already discovered the benefits of taking CBD Oil/Hemp Oil (with CBD and other cannabinoids). While it is not the purpose of this post to detail the linkage between hemp oil and the endocannabinoid system health, we do hope people educate themselves into the possibilities associated with the LEGAL uses of Industrial Hemp and its products such as CBD Oils and Tinctures as sold by stores such as the Carolina Hemp Hut and Hemp Oil Rockstar.
Since women are affected more by Fibromyalgia more than men, it's understandable that more women undertaking a CBD-enriched regimen have encountered improvements in their overall health and a reduction in symptoms associated with the Fibromyalgia. Further, it has been revealed that some of the women studies have become asymptomatic after their endocannabinoid system has been boosted with supplements of CBD and other cannabinoids.
Patients who are prescribed Lyrica, Cymbalta and Savella in addition to other related drugs may face the possibility of side effects as indicated by the FDA requirements of the Pharmaceutical companies. There are still more studies into the usage of CBD for nervous system conditions and the possible associated side effects of cannabinidiol. As of this publication, the list if adverse reactions to CBD is very short and none appear to be life-threatening as those may be for the Pharmaceutical company products.
We all have an endocannabinoid system (ECS). This system has two major types of cannabinoid receptors: CB1 receptors (primarily found in the brain) and CB2 receptors (primarily found in the immune system) are involved in a variety of physiological processes. The ECS helps regulate functions such as: sleep, immune-system responses, pain, inflammation, mood, and memory and is key in maintaining homeostasis (balance).
Cannabinoids are produced naturally within our bodies, however, when our ECS is under-active and/or you are not receiving sufficient cannabinoids, it predisposes you to a host of symptoms. For thousands of years, humans and animals consumed plants rich in cannabinoids but the eradication of all hemp related plants, by our government, has caused a deficiency of cannabinoids in our diet. Therefore, what little cannabinoids our bodies produce, may not be enough to maintain homeostasis.
Thankfully, many states have farm bills that have now allowed farmers to grow hemp plants and we are now witnessing a new era of health and wellness with the use of hemp extracts.
"Cannabinoids have similarly demonstrated the ability to block spinal, peripheral and gastrointestinal mechanisms that promote pain in headache, fibromyalgia, IBS and related disorders. The past and potential clinical utility of cannabis-based medicines in their treatment is discussed, as are further suggestions for experimental investigation of CECD via CSF examination and neuro-imaging. Migraine, fibromyalgia, IBS and related conditions display common clinical, biochemical and pathophysiological patterns that suggest an underlying clinical endocannabinoid deficiency that may be suitably treated with cannabinoid medicines."